Gerstein HC, et al. - Through an exploratory analysis of the REWIND, a multicenter, randomized, double-blind, placebo-controlled trial at 371 sites in 24 countries, experts evaluated the long-term impact of the glucagon-like peptide-1 receptor agonist dulaglutide on renal outcome of the effect of dulaglutide on cardiovascular disease. A total of 9,901 people were recruited and randomly allotted to receive dulaglutide (n=4,949) or placebo (n=4,952). The renal outcome was produced in 848 participants at an incidence rate of 3.5 per 100 person-years in the dulaglutide group and in 970 participants at an incidence rate of 4.1 per 100 person-years in the placebo group, during a median follow-up of 5.4 years comprising 51,820 person-years. In people with type 2 diabetes, long-term use of dulaglutide was correlated with decreased composite renal outcomes.